275 related articles for article (PubMed ID: 27798021)
1. Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer.
Polk A; Shahmarvand N; Vistisen K; Vaage-Nilsen M; Larsen FO; Schou M; Nielsen DL
BMJ Open; 2016 Oct; 6(10):e012798. PubMed ID: 27798021
[TBL] [Abstract][Full Text] [Related]
2. Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group.
Kwakman JJ; Simkens LH; Mol L; Kok WE; Koopman M; Punt CJ
Eur J Cancer; 2017 May; 76():93-99. PubMed ID: 28286287
[TBL] [Abstract][Full Text] [Related]
3. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer.
Dyhl-Polk A; Vaage-Nilsen M; Schou M; Vistisen KK; Lund CM; Kümler T; Appel JM; Nielsen DL
Acta Oncol; 2020 Apr; 59(4):475-483. PubMed ID: 31931649
[No Abstract] [Full Text] [Related]
4. Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review.
Saneeymehri SS; Markey KR; Mahipal A
J Oncol Pharm Pract; 2016 Jun; 22(3):552-5. PubMed ID: 25852107
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study.
Peng J; Dong C; Wang C; Li W; Yu H; Zhang M; Zhao Q; Zhu B; Zhang J; Li W; Wang F; Wu Q; Zhou W; Yuan Y; Qiu M; Chen G
Cancer Commun (Lond); 2018 May; 38(1):22. PubMed ID: 29764506
[TBL] [Abstract][Full Text] [Related]
6. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
Kosmas C; Kallistratos MS; Kopterides P; Syrios J; Skopelitis H; Mylonakis N; Karabelis A; Tsavaris N
J Cancer Res Clin Oncol; 2008 Jan; 134(1):75-82. PubMed ID: 17636329
[TBL] [Abstract][Full Text] [Related]
7. Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients.
Jin X; Bai Y; Gao L; Wu S
Cancer Chemother Pharmacol; 2019 Sep; 84(3):599-607. PubMed ID: 31203389
[TBL] [Abstract][Full Text] [Related]
8. Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study.
Osterlund P; Kinos S; Pfeiffer P; Salminen T; Kwakman JJM; Frödin JE; Shah CH; Sorbye H; Ristamäki R; Halonen P; Soveri LM; Heervä E; Ålgars A; Bärlund M; Hagman H; McDermott R; O'Reilly M; Röckert R; Liposits G; Kallio R; Flygare P; Teske AJ; van Werkhoven E; Punt CJA; Glimelius B
ESMO Open; 2022 Jun; 7(3):100427. PubMed ID: 35798468
[TBL] [Abstract][Full Text] [Related]
9. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history.
Kelly C; Bhuva N; Harrison M; Buckley A; Saunders M
Eur J Cancer; 2013 Jul; 49(10):2303-10. PubMed ID: 23583220
[TBL] [Abstract][Full Text] [Related]
10. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine.
Jensen SA; Sørensen JB
Cancer Chemother Pharmacol; 2006 Oct; 58(4):487-93. PubMed ID: 16418875
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine in breast cancer: the issue of cardiotoxicity during fluoropyrimidine treatment.
Molteni LP; Rampinelli I; Cergnul M; Scaglietti U; Paino AM; Noonan DM; Bucci EO; Gottardi O; Albini A
Breast J; 2010; 16 Suppl 1():S45-8. PubMed ID: 21050310
[TBL] [Abstract][Full Text] [Related]
12. Report of two cases of acute cardiac adverse events in patients with colorectal carcinoma receiving oral capecitabine.
Lampropoulos S; Roditis P; Koulouris E; Zafiris A; Tzimou M; Kyratlidis K; Pavlidis K; Godwin SA; Kosmas C
Anticancer Drugs; 2017 Aug; 28(7):801-807. PubMed ID: 28489615
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy.
Karakulak UN; Aladağ E; Maharjan N; Övünç K
Turk Kardiyol Dern Ars; 2016 Jan; 44(1):71-4. PubMed ID: 26875134
[TBL] [Abstract][Full Text] [Related]
14. Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal.
Upshaw JN; O'Neill A; Carver JR; Dimond EP; Denlinger CS; Kircher SM; Wagner LI; Ky B; Brell JM
Clin Colorectal Cancer; 2019 Mar; 18(1):44-51. PubMed ID: 30348619
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors.
Polk A; Vaage-Nilsen M; Vistisen K; Nielsen DL
Cancer Treat Rev; 2013 Dec; 39(8):974-84. PubMed ID: 23582737
[TBL] [Abstract][Full Text] [Related]
16. Cardiac toxicity with capecitabine, vinorelbine and trastuzumab therapy: case report and review of fluoropyrimidine-related cardiotoxicity.
Le Brun-Ly V; Martin J; Venat-Bouvet L; Darodes N; Labourey JL; Genet D; Tubiana-Mathieu N
Oncology; 2009; 76(5):322-5. PubMed ID: 19307737
[TBL] [Abstract][Full Text] [Related]
17. Cardiotoxicity of capecitabine: Captions not to bin.
De Gennaro L; Brunetti ND; Resta M; Rutigliano D; Tarantini L; Caldarola P
Int J Cardiol; 2017 Feb; 229():6. PubMed ID: 27940005
[No Abstract] [Full Text] [Related]
18. [Cardiotoxicity induced by 5-fluorouracil or capecitabine].
Jensen SA; Baeksgaard L; Petersen LN; Reiter L; Sørensen JB
Ugeskr Laeger; 2010 Jan; 172(1):48-51. PubMed ID: 20056096
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine cardiotoxicity--case reports and literature review.
Manojlovic N; Babic D; Stojanovic S; Filipovic I; Radoje D
Hepatogastroenterology; 2008; 55(85):1249-56. PubMed ID: 18795667
[TBL] [Abstract][Full Text] [Related]
20. Rapidly developing heart failure from capecitabine cardiotoxicity: a case study.
Ambesh P; Zivari K; Obiagwu C; Shetty V; Kamholz S; Hollander G; Shani J
Br J Clin Pharmacol; 2018 Apr; 84(4):800-802. PubMed ID: 29336052
[No Abstract] [Full Text] [Related]
[Next] [New Search]
